Bio-Techne Corporation
NASDAQ:TECHBiotechnology
-$1.03 today
- Market cap
- $11.43B
- Beta
- 1.36
- P/E (TTM)
- 78.3
- EPS (TTM)
- $0.70
- Dividend yield
- 0.58%
Volume 2.63M
Average 2.66M
TECH Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Bio-Techne CorporationNASDAQ: TECH
Stock-Based Compensation · Q1 FY2027 · quarter ended Sep 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2027 stock-based compensation of $13.41M rose 14.8% year over year, behind the +56.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 156.3% from the prior quarter. Over 3 fiscal years it compounded at +1.8% a year.
Context
- Stock-based compensation amounted to 3.4% of revenue in FY2026, unchanged from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +14.8% toward the trailing-twelve-month pace of +56.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2026
- 41.37M USD
- Year-over-year change
- +1.3%
- 4-year CAGR
- -0.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 41.37M | +1.3% |
| FY2025 | 2025-06-30 | 40.83M | +7.3% |
| FY2024 | 2024-06-30 | 38.04M | -3.0% |
| FY2023 | 2023-06-30 | 39.23M | -7.0% |
| FY2022 | 2022-06-30 | 42.18M | — |
Stock-Based Compensation vs competitors
How TECH compares with its peers on the latest reported figures
- TECH's LTM Sep 2026 stock-based compensation of $43.09M is the 6th largest of the 11 companies compared; the peer median is $41.38M.
- Its year-over-year change of +56.0% is the highest of 9, against a peer median of -17.2%.
- Stock-based compensation amounts to 3.5% of revenue for TECH, versus a peer median of 1.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $297M | +1.7% | +0.3% | 1.2% | |
| LTM Jul 2026 | $131M | +2.3% | +0.8% | 1.8% | |
| LTM Jun 2026 | $98.74M | -20.9% | -7.3% | 16.0% | |
| LTM Sep 2026 | $84M | — | +0.3% | 0.2% | |
| LTM Jun 2026 | $45.8M | +43.1% | -1.6% | 1.8% | |
| LTM Sep 2026 | $43.09M | +56.0% | +1.8% | 3.5% | |
| LTM Jun 2026 | $36.96M | -13.6% | +0.6% | 1.8% | |
| LTM Jul 2026 | $24.43M | -27.0% | -23.7% | 0.8% | |
| LTM Mar 2026 | $12.88M | -49.1% | -22.9% | 85.6% | |
ALMRAlamar Biosciences, Inc. | FY2025 | $2.87M | — | — | 3.9% |
| LTM Jun 2026 | $0 | -100.0% | -10.0% | 0.0% | |
| Peer median (excluding TECH) | $41.38M | -17.2% | -1.6% | 1.8% | |
Competitors are the stored peer set for TECH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Net Income | 263.1M | 285.44M | 168.07M | 73.4M | 181.86M |
| Depreciation & Amortization | 101.07M | 107.24M | 111.71M | 109.9M | 97.36M |
| Deferred Income Tax | 6.82M | (29.57M) | (39.45M) | (51.11M) | 13.2M |
| Stock-Based Compensation | 42.18M | 39.23M | 38.04M | 40.83M | 41.37M |
| Change in Working Capital | (69.52M) | (90.58M) | (10.11M) | 11.54M | (41.3M) |
| Accounts Receivables | (57.6M) | (23.36M) | (31.13M) | 42.6M | (10.79M) |
| Inventory | (32.01M) | (30.17M) | (14.22M) | (18.14M) | (8.23M) |
| Accounts Payables | 12.74M | (7.91M) | 25.77M | (13.95M) | 3.18M |
| Other Working Capital | 7.35M | (29.14M) | 9.47M | 1.04M | (25.46M) |
| Other Non-Cash Items | (18.38M) | (57.37M) | 30.71M | 102.99M | (406K) |
| Operating Cash Flow | 325.27M | 254.39M | 298.98M | 287.56M | 292.07M |
| Capital Expenditures | (44.91M) | (38.24M) | (62.88M) | (31.01M) | (28.85M) |
| Acquisitions (Net) | 0 | (83.36M) | (169.71M) | (15M) | 4.62M |
| Purchases of Investments | (25M) | (20.5M) | (5.53M) | (5.53M) | 0 |
| Sales of Investments | 26.06M | 108.46M | 28.08M | 1.09M | 6.04M |
| Other Investing Activities | (53M) | (232M) | 7M | 15.26M | 0 |
| Investing Cash Flow | (96.85M) | (265.65M) | (203.03M) | (35.18M) | (18.19M) |
| Debt Repayment | (85.5M) | 94M | (31M) | 27M | (146M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 80.62M |
| Common Stock Repurchased | (160.95M) | (19.56M) | (80.04M) | (275.73M) | (41.68M) |
| Dividends Paid | (50.19M) | (50.29M) | (50.42M) | (50.39M) | (49.92M) |
| Other Financing Activities | 53.78M | (1.54M) | 39.06M | 45.22M | (12.14M) |
| Financing Cash Flow | (242.85M) | 22.62M | (122.4M) | (253.91M) | (169.11M) |
| Effect of Forex Changes | (12.09M) | (3.36M) | (2.33M) | 11.93M | (2.24M) |
| Net Change in Cash | (26.52M) | 8M | (28.78M) | 10.4M | 102.53M |
| Free Cash Flow | 280.36M | 216.15M | 236.1M | 256.55M | 263.22M |
Bio-Techne Corporation
NASDAQ:TECH
Intrinsic Alpha fair value
Locked
Current Price
$72.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.